Apimeds Pharmaceuticals reports resignations of two board directors

Apimeds Pharmaceuticals US, Inc. reported that on December 5, 2025, two members of its Board of Directors resigned.

Rhea-AI Filing Summary

Apimeds Pharmaceuticals US, Inc. reported that on December 5, 2025, two members of its Board of Directors resigned. Director Dr. Vin Menon and Independent Director Amir A. Dossal both stepped down from their board positions.

The company stated that these resignations were not due to any disagreement regarding its operations, policies, or practices. Dr. Menon continues to serve as Chief Executive Officer, as he signed the report in that capacity. The filing focuses solely on this board-level leadership change and does not include financial results or transaction details.

Insights

Corporate Governance Analyst

Two board members, including an independent director, resigned, raising governance and oversight questions despite stated lack of disagreement.

Apimeds Pharmaceuticals US, Inc. reported that on December 5, 2025, Dr. Vin Menon, a Director, and Amir A. Dossal, an Independent Director, resigned from the Board of Directors. The company states the resignations were not due to any disagreement on operations, policies, or practices. The filing shows that Dr. Menon continues to act as Chief Executive Officer, as he signs the report in that capacity on December 10, 2025, which means the leadership change is limited to board roles.

This event reduces the size of the Board and removes at least one independent voice, which may affect board independence and committee composition, depending on remaining directors. The stated absence of disagreement may limit concerns about immediate internal conflict, but the loss of directors still narrows perspectives at the top level. Compliance with exchange governance requirements, such as minimum independent director counts for NYSE American, becomes a key consideration after these departures.

Key items to watch now include how and when the company fills these board vacancies, especially the independent seat, and any resulting changes in committee assignments. Any follow-up disclosure describing new director appointments, board structure, or committee realignments in upcoming 8-Ks or proxy materials over the next few months will help clarify the lasting governance impact.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Apimeds Pharmaceuticals US, Inc. (APUS) disclose in this 8-K?

Apimeds Pharmaceuticals US, Inc. disclosed that two members of its Board of Directors, Dr. Vin Menon and Amir A. Dossal, resigned from the board on December 5, 2025.

Were the director resignations at Apimeds (APUS) due to disagreements with the company?

No. The company stated that the resignations of Dr. Vin Menon and Amir A. Dossal were not the result of any disagreement with Apimeds on its operations, policies, or practices.

Does Dr. Vin Menon remain involved with Apimeds Pharmaceuticals US, Inc. after resigning from the board?

Yes. Although he resigned as a Director, Dr. Vin Menon signed the report as Chief Executive Officer, indicating he continues in that executive role.

Which board roles changed at Apimeds (APUS) according to this filing?

The filing reports the resignation of Director Dr. Vin Menon and Independent Director Amir A. Dossal from the Board of Directors of Apimeds Pharmaceuticals US, Inc.

Does this Apimeds (APUS) 8-K include any financial or earnings information?

No. The disclosure focuses on board-level changes under Item 5.02 and does not present financial results, earnings data, or major transaction details.

On what date did the Apimeds (APUS) director resignations occur?

Both director resignations occurred on December 5, 2025, which is identified as the date of the earliest event reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/10/2025 - 09:20 AM Learn about SEC filing dates

false 0001894525 0001894525 2025-12-05 2025-12-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 5, 2025

Apimeds Pharmaceuticals US, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-42545		85-1099700
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

100 Matawan Rd, Suite 325 Matawan, New Jersey		07747
(Address of principal executive offices)		(Zip code)

Registrant’s telephone number, including area code: (848) 201-5010 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		APUS		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 5, 2025, Dr. Vin Menon, a Director of Apimeds Pharmaceuticals US, Inc. (the “Company”), and Amir A. Dossal, an Independent Director of the Company, resigned from their positions on the Company’s Board of Directors. The resignations were not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Apimeds Pharmaceuticals US, Inc.
Date: December 10, 2025	By:	/s/ Vin Menon
	Name:	Dr. Vin Menon
	Title:	Chief Executive Officer

2